Tetramatrix is a proprietary, fully synthetic biomaterial that is compatible with minimally invasive administration techniques and does not induce any foreign body reaction, a genuine biostealth platform technology. The company has active development programs in the areas of regenerative medicine and mRNA delivery.
As a world-class researcher with decades of experience in translational research, Simin manages and drives our production program. Combining both a calm temperament and a meticulous nature, Simin is our production and research North Star.
Ruth has unparalleled experience in the quality and regulatory functions of the global medical device industry, which are critical in her role to obtain registration and market clearance for Tetramatrix. Ruth has a unique ability to be both dynamic and meticulous in how she applies her skill set – a rarity in the industry.
Will provides the commercial context to define and deliver the Tetratherix mission, vision and culture. Will’s prior success in commercialisation and development of life-changing MedTech innovations are paramount to the company’s global ambitions.
Farshad is a Chemical and Biomolecular Engineering researcher with a distinguishable scientific track record in material innovation and biomedical technologies. Farshad leads our research programs and creatively marries our foundational science with global healthcare needs.
Ali is a world-renowned researcher and inventor of Tetramatrix and has continued the development of the technology using his technical and entrepreneurial vision. Ali’s scientific approach to problem-solving and his tenacity are central to bringing the technology into the hands of clinicians.
Kim’s proficient and driven management of our clinical trial program has enabled us to establish an adoptable and efficient cadence in our clinical validation. Her calm and confident decision-making complements her ability to energise those around her.
As an engineer, Terence is armed with the experience and understanding of bespoke chemical manufacturing. A natural problem solver with the ability to think outside the box, Terence has been instrumental in process design and optimisation to allow production of Tetramatrix at scale.
Jeff’s decades of experience in successful commercialisation of medical innovations forms a platform that helps to define our commercial development program, including key partnership management and pipeline strategy. Jeff’s extensive knowledge of execution and accountability in the market ensures that our development program meets our commercial objectives.
Dax is a specialist periodontist with a passion to simplify and improve techniques relating to dental implant surgeries and bone augmentation procedures. Dax is a long-time supporter of Tetratherix and was the first surgeon to explore Tetramatrix in a clinical setting.
For nearly a decade, Rob has been ranked as Australia’s highest recommended patent and technology licensing lawyer. He specializes in the commercialisation of novel technologies, and in aspects of major corporate transactions related to intellectual property.
Ali is the CEO of the Terasaki Institute and former Professor at the University of California, Los Angeles, Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering. Ali has been selected by Thomson Reuters as one of the World’s Most Influential Minds since 2014.
Drew is a board-certified plastic and reconstructive surgeon with a passion for complex skin cancer excision and surgical reconstruction. Drew has been the winner of the prestigious Emmett Prize for most outstanding registrar research in Australia and New Zealand.
Tetramatrix solution provides the first and only carrier system that increases the stability of mRNA+LNP formulations, allowing shipment and storage at ambient condition while enabling their nasal delivery.
Tetratherix’s solution is the first and only injectable product that can block the annulus to prevent reherniation following decompression surgery.
Tetratherix’s solution is the only flowable matrix that can be used intraoperatively to provide an internal cushioning effect to physically decrease mechanical tension and therefore reduce scar formation after any surgery, such as surgical reconstruction, arthroplasty and caesarean procedures.
Tetramatrix can be mixed with any bone grafting material, preferred by the clinicians to form an easy to apply composite to simplify complex procedures. The matrix works synergistically with the graft to accelerate soft and hard tissue regeneration.
Tetratherix’s hydrogel technology used as an enabling carrier for targeted delivery of novel therapeutics. This is an exciting development in our Biodelivery program and validates the potential of our technology to effectively deliver & preserve the bioactivity of a range of therapeutics – Journal of Pharmaceutics
Tetramatrix as a regenerative platform for tissue agnostic regeneration. Our technology was selected as the cover feature, the fluid network is temperature responsive and transitions into an adhesive hydrogel matrix upon administration. The resulting scaffold moulds within any defect and provides a regenerative network for cell in growth and…